Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...

Most people with a condition known as chronic rhinosinusitis with nasal polyps (CRSwNP) are able to control their symptoms by using medicines that are sprayed into the nose or taken by mouth. But some ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...

Dupixent (dupilumab) is a prescription drug. It’s used to treat chronic (ongoing) rhinosinusitis (nasal and sinus inflammation) due to nasal polyps. Dupixent is a biologic drug and does not come in a ...

Regeneron and Sanofi are at it again with their ongoing Dupixent DTC campaign dubbed DU More. The pair of drugmakers rolled out the latest iteration of the campaign on Monday morning, right in time ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...